DUBLIN, January 04, 2022– (BUSINESS WIRE) – The report “Cancer Microbiome Sequencing Market – A Global and Regional Analysis: Focus on Supply, Application, Technology, End User, and Region – Analysis and Forecast, 2021-2031 »has been added to ResearchAndMarkets.com offer.
In 2020, the global cancer microbiome sequencing market was valued at $ 155.5 million and is expected to reach $ 1,216.2 million by 2031, growing at a CAGR of 20.01% over the course of the forecast period 2021-2031.
Prescient Medicine Holdings, Inc.
Novogene Co., Ltd.
Oxford Nanopore Technologies plc.
OraSure Technologies, Inc.
Pacific Biosciences of California, Inc.
Thermo Fisher Scientific Inc.
Zymo Research Company
The market is driven by a number of factors including the focus on the potential of the microbiome in cancer, the global increase in cancer prevalence, and the decreasing cost of sequencing.
Currently, the cancer microbiome sequencing industry is experiencing an upsurge due to the increasing emphasis placed on the potential of the microbiome in cancer, the global increase in cancer prevalence and decreasing sequencing costs. . In addition, biotech companies are focused on developing cancer microbiome sequencing solutions for applications including translational research and diagnostics, further helping researchers and clinicians discover information relating to the influence of cancer. microbiome on the manifestation and progression of cancer.
The development of cancer microbiome sequencing products and services has enabled the research community to establish effective strategies to discover new cancer biomarkers associated with the microbiome, which could be exploited for the development of microbiome sequencing products. cancer for clinical use.
In the research report, the market is segmented on the basis of supply, application, technology, end-users, and region. Each of these segments covers the market snapshot over the projected years, market revenue tilt, underlying patterns and trends using analyzes on the obtained primary and secondary data.
The exponential increase in the number of cancer cases worldwide has created a buzz among biotech companies to invest more in the development of new diagnostic tools based on the microbiome to help doctors provide early detection of cancer. Due to its broad product portfolio and massive geographic presence, Illumina, Inc. has been the primary player in the cancer microbiome sequencing ecosystem.
Based on region, North America holds the largest share of the cancer microbiome sequencing market due to the presence of market leaders such as Illumina, Inc. Translation research. In addition, increased fund injections by federal organizations and increased investments for product development, among others. Apart from this, the Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period, 2021-2031. This is mainly attributed to underlying factors such as increased awareness of healthcare, a stable economy leading to a greater focus on research and widespread adoption of advanced cancer diagnostics, among others.
Growing focus on the potential of the microbiome in cancer
Global increase in cancer prevalence
Reduced cost of sequencing
Regulatory challenges for direct-to-consumer (DTC) businesses
Lack of high complexity test centers
Existing diagnostic confidence in conventional cancer diagnostics
Key questions addressed in this report:
How is cancer microbiome sequencing revolutionizing the field of oncology?
What are the major market drivers, challenges, and opportunities in the global Cancer Microbiome Sequencing market?
What are the underlying structures driving emerging trends in the global Cancer Microbiome Sequencing market?
How has the COVID-19 pandemic impacted the global cancer microbiome sequencing ecosystem?
What are the key development strategies implemented by the major players in order to remain in the competitive market?
What are the main regulatory implications in developed and developing regions regarding the use of cancer microbiome sequencing?
What are the potential barriers to entry that businesses wishing to enter a particular region should face?
How is each market segment expected to grow during the forecast period 2021-2031, and what are the expected revenue generated by each of the segments?
What are the growth opportunities for cancer microbiome sequencing companies in their region of operation?
Who are the major players with significant offerings in the global Cancer Microbiome Sequencing market?
Which companies are expected to be very disruptive in the future, and why?
For more information on this report visit https://www.researchandmarkets.com/r/1dj6sa
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220104005614/en/
Laura Wood, Senior Press Director
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900